ABSTRACT

Castleman´s disease is a disorder characterized by reactive lymphoid hyperplasia and progressive growth of benign tumors of lymphoid tissue and increased predisposition to develop lymphoma. The real prevalence is unknown; it has been estimated at less than 1/100.000. Even this is a rare disease, it should be considered in the differential diagnosis of mediastinal tumors with increase uptake in the CT scan.

KEYWORDS

Castleman´s disease, mediastinal tumor.

REFERENCES

1. Castilletti HJM, Vargas SDM, Martinez M, Rojas N. Enfermedad Castleman. A propósito de dos casos. Arch Venez Pueri Pediatr 2008;71:54-58.

2. Sarrot-Reynauld F. Castleman’s disease. Orphanet encyclopedia 2001;1-4.

3. Viveros ALM, Sánchez MJF. Enfermedad de Castleman. Reporte de un caso en adolescente. An Med Asoc Med Hosp ABC 2001;46:193-196.

4. Bonekamp D, Horton HM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics 2011;31:1793-1807.

5. Rodríguez SH, Buchaca FE, Machado PI, Pérez RG, Pérez CD. Enfermedad de Castleman. Presentación de cinco casos. An Med Interna (Madrid) 2005;22:24-27.

6. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal Castleman’s disease. World J Surg Oncol 2005;3:1-9.

7. Sobrevilla-Calvo PJ, Avilés-Salas A, Cortés-Padilla DE, Rivas-Vera S. Características clinicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.

8. El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16:497-451.

9. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989;74:1360-1367.

10. Nakazawa-Soken JS, Kazuyuki Yoshizaki. Up-regulation of hepcidin by interleukin-6 contributes to anemia of inflammation in multicentric Castleman’s disease. Mini Review 2012;32:99-106.